Trial Profile
Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Acute coronary syndromes; Ischaemic heart disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms LILACS
- 10 Sep 2021 Status changed from active, no longer recruiting to completed.
- 18 Mar 2021 Planned End Date changed from 1 Jun 2021 to 1 Aug 2022.
- 18 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Aug 2021.